



DBV Technologies and BIOPROJET Enter Into Distribution Agreement For Diallertest® Milk

DBV Technologies strengthens its distribution network for leading cow's milk allergy paediatric diagnostic

Paris, France – 12 October 2009 – DBV Technologies, a biopharmaceutical company specialising in the development of non-invasive epicutaneous diagnostics and immunotherapies for allergies, announced today that it has signed a distribution agreement with BIOPROJET pharma for DBV's Cow's Milk protein allergy diagnostic, Diallertest® Milk. Under the terms of the agreement, BIOPROJET Pharma will promote and distribute Diallertest® Milk in France.

BIOPROJET pharma, a French paediatric focused pharmaceutical company, markets a number of products in France including Tiorfan® (a leading anti-diarrheal drug) Fanomer® (a nasal spray for children) and Fanolyte® (an oral rehydration solution). Since 2002, BIOPROJET Pharma has extended its distribution networks to include major European and overseas markets.

“We are extremely pleased to have signed this distribution deal with BIOPROJET Pharma,” said DBV Technologies Chairman and CEO Jean François Biry. “The agreement will enable wider access to a diagnostic for a condition that is very difficult to diagnose which is also the cause of significant pain and distress for infants.”

“Diallertest® Milk is a non-invasive, easy to use and pain free approach for the diagnosis of cow's milk protein allergy. It fits well with our existing product range and we look forward to working with DBV to make Diallertest® Milk more widely available throughout Europe”, commented BIOPROJET Pharma CEO Dr. Jeanne-Marie Lecomte.

DBV Technologies is currently working on the further development of its Diallertest® product range for the diagnosis of wheat, soya and dustmite allergies in children.